Early survival advantage of off-pump CABG gradually lost during first five years
FRIDAY, Feb. 6, 2026 (HealthDay News) — Perioperative morbidity and mortality are slightly reduced with coronary artery bypass grafting (CABG) performed off-pump (OPCAB) by experienced surgeons, according to a study presented at the annual meeting of the Society of Thoracic Surgeons, held from Jan. 29 to Feb. 1 in New Orleans.
John Puskas, M.D., from Emory University Hospital Midtown in Atlanta, and colleagues examined the short-, intermediate-, and long-term outcomes after isolated OPCAB versus on-pump CABG (ONCAB), both performed by experienced high-volume surgeons. The primary end point was 0- to 15-year all-cause mortality.
The study included 184,655 OPCAB cases performed by 205 experienced OPCAB surgeons and 1,340,404 ONCAB cases performed by 1,566 experienced ONCAB surgeons. A total of 184,550 very closely matched pairs were included in a greedy propensity score-matching analysis. The researchers found that incomplete revascularization occurred more often with OPCAB (14.4 versus 8.1 percent); an average of 0.20 fewer grafts were received by OPCAB patients. In OPCAB, multiarterial grafting was more frequent (14.5 versus 9.6 percent); an average of 0.10 more arterial grafts were received by OPCAB patients. Significantly better perioperative/30-day outcomes were experienced by OPCAB versus ONCAB patients, including operative mortality, stroke, new atrial fibrillation, renal failure, return to the operating room, prolonged ventilation, and any transfusion. A gradual diminishing return of the early OPCAB survival advantage was seen with follow-up through five years. For patients with one-vessel disease, but not for those with multivessel disease, a small OPCAB survival advantage reappeared through 15-year follow-up.
“Our results emphasize the importance of surgeon experience, complete revascularization, and use of multiple arterial grafts — regardless of surgical technique,” Puskas said in a statement.
Comparable Progression Risk Seen With Ablation Versus Surgery for T1a Renal Cell Carcinoma 
Perioperative Enfortumab Vedotin + Pembrolizumab Tied to Improved Outcomes With Bladder Cancer .jpg)
Bypassing the Closest Surgical Site for Urgent Care Tied to Worse Outcomes 
Postadenotonsillectomy Respiratory Volume Monitoring Feasible in Obstructive Sleep Apnea 
Sucrose Reduces Pain During, Just After Venipuncture in Neonates 
Short-Term Surgical Outcomes at Rural Facilities Similar to Those in More Distant, Urban Facilities 
No Increase Seen in Neovascular AMD Risk After Cataract Surgery 
Weekly, High-Risk Rounds Reduced Hospital-Acquired Conditions in Pediatric ICU 
